Trial Profile
An Exploratory Phase 2 Study to Determine Safety, Tolerability and Impact of BGP-15 on cardiac fibrosis and ventricular remodelling in patients with Non-Ischaemic Dilated Cardiomyopathy (NIDCM)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2019
Price :
$35
*
At a glance
- Drugs BGP 15 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions
- Sponsors N-Gene Research Laboratories
- 28 Nov 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Jun 2016 New trial record